Figure 5. Neutralization by hMab5.17 targeting WT and variant SARS-CoV-2.

(A) Neutralizing activity of hMab5.17 against the authentic Alpha, Beta, Gamma, and Delta viruses compared with that against the original SARS-CoV-2 strain. The horizontal dotted line indicates 50% neutralization. (B) hMab5.17 neutralized the pseudoviruses SARS-CoV-2, SARS-CoV-1, and some dominant SARS-CoV-2 S natural variants. Restriction of pseudovirus entry by humanized Abs is shown as a percentage of relative inhibition. The filled circles show the corresponding authentic viruses in A, and empty circles indicate only pseudotyped viruses. (C) hMab5.17 showed high therapeutic efficacy in Delta variant–infected hamsters. The body weight change (%) was monitored daily over 6 days. Each group (n = 4) was challenged intranasally with 10³ TCID₅₀ of the SARS-CoV-2 Delta variant and intraperitoneally injected with different doses of humanized Abs or PBS control treatments 3 hours and again at 1 day after infection. Significance was determined by 2-way ANOVA followed by Tukey multiple-comparison test. The data are reported as mean values. All data are reported as the mean ± SEM. **P < 0.01, ****P < 0.0001 compared with the control.